|
2020 Journal Article Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialAscierto, Paolo A., Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Maio, Michele, Middleton, Mark R., de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Lobo, Maurice, de Pril, Veerle, Loffredo, John, Larkin, James and Weber, Jeffrey (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 21 (11), 1465-1477. doi: 10.1016/S1470-2045(20)30494-0 |
|
2020 Journal Article Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patientsAoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3 |
|
2020 Journal Article Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iDummer, Reinhard, Lebbé, Celeste, Atkinson, Victoria, Mandalà, Mario, Nathan, Paul D., Arance, Ana, Richtig, Erika, Yamazaki, Naoya, Robert, Caroline, Schadendorf, Dirk, Tawbi, Hussein A., Ascierto, Paolo A., Ribas, Antoni, Flaherty, Keith T., Pakhle, Neha, Campbell, Catarina D., Gusenleitner, Daniel, Masood, Aisha, Brase, Jan C., Gasal, Eduard and Long, Georgina V. (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 26 (10), 1557-1563. doi: 10.1038/s41591-020-1082-2 |
|
2020 Journal Article The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitionsGebhardt, Christoffer, Ascierto, Paolo, Atkinson, Victoria, Corrie, Pippa, Dummer, Reinhard and Schadendorf, Dirk (2020). The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. European Journal of Cancer, 138, 68-76. doi: 10.1016/j.ejca.2020.07.016 |
|
2020 Journal Article Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BCarlino, Matteo S., Menzies, Alexander M., Atkinson, Victoria, Cebon, Jonathan S., Jameson, Michael B., Fitzharris, Bernard M., McNeil, Catriona M., Hill, Andrew G., Ribas, Antoni, Atkins, Michael B., Thompson, John A., Hwu, Wen-Jen, Hodi, F. Stephen, Guminski, Alexander D., Kefford, Richard, Wu, Haiyan, Ibrahim, Nageatte, Moreno, Blanca Homet and Long, Georgina V. (2020). Long-term Follow-up of Standard-Dose Pembrolizumab plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research, 26 (19), 5086-5091. doi: 10.1158/1078-0432.CCR-20-0177 |
|
2020 Journal Article Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaDummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M., Chiarion Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V. and Schadendorf, Dirk (2020). Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. The New England Journal of Medicine, 383 (12), 1139-1148. doi: 10.1056/NEJMoa2005493 |
|
2020 Journal Article Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series reportHultin, Sebastian, Nahar, Kazi, Menzies, Alexander M., Long, Georgina V., Fernando, Suran L., Atkinson, Victoria, Cebon, Jonathan and Wong, Muh Geot (2020). Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrology, 21 (1) 391, 1-9. doi: 10.1186/s12882-020-02044-9 |
|
2020 Journal Article Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanomaMason, Robert, Dearden, Helen C., Nguyen, Bella, Oon, Jennifer S., Smith, Jessica Louise, Randhawa, Manreet, Mant, Andrew, Warburton, Lydai, Lo, Serigne, Meniawy, Tarek, Guminski, Alexander, Parente, Phillip, Ali, Sayed, Haydon, Andrew, Long, Georgina V., Carlino, Matteo S., Millward, Michael, Atkinson, Victoria G. and Menzies, Alexander M. (2020). Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell and Melanoma Research, 33 (2) pcmr.12831, 358-365. doi: 10.1111/pcmr.12831 |
|
2020 Journal Article Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialDummer, Reinhard, Brase, Jan C., Garrett, James, Campbell, Catarina D., Gasal, Eduard, Squires, Matthew, Gusenleitner, Daniel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Flaherty, Keith, Larkin, James, Robert, Caroline, Kefford, Richard, Kirkwood, John M., Hauschild, Axel, Schadendorf, Dirk and Long, Georgina V. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The Lancet Oncology, 21 (3), 358-372. doi: 10.1016/S1470-2045(20)30062-0 |
|
2020 Journal Article Intratumoural immunotherapies in oncologyXu, Wen, Atkinson, Victoria G. and Menzies, Alexander M. (2020). Intratumoural immunotherapies in oncology. European Journal of Cancer, 127, 1-11. doi: 10.1016/j.ejca.2019.12.007 |
|
2020 Journal Article Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trialEggermont, Alexander M. M., Kicinski, Michal, Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, Van Den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C., Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Van Akkooi, Alexander, Robert, Caroline and Suciu, Stefan (2020). Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncology, 6 (4), 519-527. doi: 10.1001/jamaoncol.2019.5570 |
|
2020 Journal Article Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)Atkinson, Victoria, Sandhu, Shahneen, Hospers, Geke, Long, Georgina V., Aglietta, Massimo, Ferrucci, Pier F., Tulyte, Skaiste, Cappellini, Gian Carlo Antonini, Soriano, Virtudes, Ali, Sayed, Poprach, Alexandr, Cesas, Alvydas, Rodriguez-Abreu, Delvys, Lau, Mike, De Jong, Egbert, Legenne, Philippe, Stein, Dara, King, Brianna and Van Thienen, Johannes V. (2020). Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 30 (3), 261-267. doi: 10.1097/CMR.0000000000000654 |
|
2020 Journal Article Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M. A., Millward, M., Patel, S. P., Haydon, A., Johnson, D. B., Lo, S., Blank, C. U., Sandhu, S., Carlino, M. S., Larkin, J. M.G., Menzies, A. M. and Long, G. V. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Annals of Oncology, 31 (8), 1075-1082. doi: 10.1016/j.annonc.2020.04.471 |
|
2020 Journal Article Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysisBhave, Prachi, Pallan, Lalit, Long, Georgina V., Menzies, Alexander M., Atkinson, Victoria, Cohen, Justine V., Sullivan, Ryan J., Chiarion-Sileni, Vanna, Nyakas, Marta, Kahler, Katharina, Hauschild, Axel, Plummer, Ruth, Trojaniello, Claudia, Ascierto, Paolo A., Zimmer, Lisa, Schadendorf, Dirk, Allayous, Clara, Lebbe, Celeste, Maurichi, Andrea, Santinami, Mario, Roy, Severine, Robert, Caroline, Lesimple, Thierry, Patel, Sapna, Versluis, Judith M., Blank, Christian U., Khattak, Adnan, Van der Westhuizen, Andre, Carlino, Matteo S. ... Haydon, Andrew (2020). Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer, 124 (3), 574-580. doi: 10.1038/s41416-020-01121-y |
|
2019 Journal Article Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient ProgramMartin-Algarra, Salvador, Hinshelwood, Rebecca, Mesnage, Soizick, Cebon, Jonathan, Ferrucci, Pier Francesco, Aglietta, Massimo, Neyns, Bart, Chiarion-Sileni, Vanna, Lindsay, Colin R., Del Vecchio, Michele, Linardou, Helen, Merelli, Barbara, Tonini, Giuseppe, Atkinson, Victoria, Freivogel, Klaus, Stein, Dara, Dalland, Lindi, Lau, Mike, Legenne, Philippe, Queirolo, Paola and Millward, Michael (2019). Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 29 (5), 527-532. doi: 10.1097/CMR.0000000000000608 |
|
2019 Journal Article Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesPires da Silva, Ines, Glitza, Isabella C., Haydu, Lauren E., Johnpulle, Romany, Banks, Patricia D., Grass, George D., Goldinger, Simone M. A., Smith, Jessica L., Everett, Ashlyn S., Koelblinger, Peter, Roberts-Thomson, Rachel, Millward, Michael, Atkinson, Victoria G., Guminski, Alexander, Kapoor, Rony, Conry, Robert M., Carlino, Matteo S., Wang, Wei, Shackleton, Mark J., Eroglu, Zeynep, Lo, Serigne, Hong, Angela M., Long, Georgina V., Johnson, Douglas B. and Menzies, Alexander M. (2019). Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 32 (4), 553-563. doi: 10.1111/pcmr.12775 |
|
2019 Journal Article Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literatureXu, Wen, Moor, Rebecca J., Walpole, Euan T. and Atkinson, Victoria G. (2019). Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Research, 29 (3), 333-337. doi: 10.1097/CMR.0000000000000586 |
|
2019 Journal Article Reply to E. Hindié and K.R. HessLong, Georgina V., Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M. and Hauschild, Axel (2019). Reply to E. Hindié and K.R. Hess. Journal of Clinical Oncology, 37 (15), 1356-1358. doi: 10.1200/JCO.19.00004 |
|
2019 Journal Article Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialSchadendorf, Dirk, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Lesimple, Thierry, Plummer, Ruth, Schachter, Jacob, Dasgupta, Kohinoor, Manson, Stephanie, Koruth, Roy, Mookerjee, Bijoyesh, Kefford, Richard, Dummer, Reinhard, Kirkwood, John M. and Long, Georgina V. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 20 (5), 701-710. doi: 10.1016/S1470-2045(18)30940-9 |
|
2019 Conference Publication Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibitionAgarwala, Sanjiv S., Ross, Merrick I., Zager, Jonathan, Shirai, Keisuki, Essner, Richard, Smithers, Bernard M., Atkinson, Victoria, Sarson, David and Wachter, Eric A. (2019). Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibition. LONDON: BMC. |
